Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has announced significant advancements in its Phase 3 program for HLP003, its lead candidate for major depressive disorder (MDD). The company completed enrollment in the APPROACH study, a pivotal Phase 3 trial, and expects to report topline data in the fourth quarter of 2026. This milestone brings the company closer to potentially offering a new treatment option for the millions of patients who do not adequately respond to existing antidepressants.
The completion of enrollment in APPROACH is a critical step in the regulatory pathway for HLP003, which has already received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. If successful, HLP003 could become an adjunctive treatment for MDD, addressing a significant unmet medical need. The company is also enrolling patients in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program, and participants are rolling over into the EXTEND study, which will provide long-term safety and efficacy data. These studies are designed to support a New Drug Application submission to the FDA.
In addition to the HLP003 program, Helus Pharma is advancing HLP004 for generalized anxiety disorder (GAD). Phase 2 results showed a statistically significant and clinically meaningful improvement from baseline, and the company expects to complete the design of the next study by the end of the third quarter of 2026. This progress underscores the company's commitment to addressing multiple mental health conditions with its proprietary NSA platform.
Financially, Helus Pharma reported cash and cash equivalents of $166.4 million as of June 30, 2026. The company posted a net loss of $47.8 million for the second quarter, compared to a net loss of $24.6 million in the same period last year. Cash-based operating expenses increased to $37.5 million from $23.9 million, reflecting the costs associated with the ongoing Phase 3 trials. The company believes its current cash position is sufficient to fund operations into the second half of 2027, which will allow it to reach key milestones, including the HLP003 topline data readout and the advancement of HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027.
The implications of these developments are substantial for the mental health community. Major depressive disorder affects over 280 million people worldwide, and a significant proportion do not achieve remission with current therapies. HLP003, if approved, could offer a new mechanism of action that promotes neuroplasticity, potentially providing durable improvements in symptoms. The Breakthrough Therapy Designation highlights the potential of HLP003 to offer a significant improvement over existing treatments. For investors, the approaching data readout represents a major catalyst, while for patients and healthcare providers, it brings hope for a new therapeutic option.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing NSAs that target serotonin pathways believed to promote neuroplasticity. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's newsroom at https://ibn.fm/yfpOW.
